MELISSA COCHRAN: Open Payments
NPI 1104570886 · RALEIGH, NC. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$344 in 15 payments from 7 companies in 2025. Trend: 2023 $353 · 2024 $201 · 2025 $344
Food & beverage: $344
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 3 | $72 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $70 |
| Janssen Pharmaceuticals, Inc | 2 | $56 |
| Otsuka America Pharmaceutical, Inc. | 2 | $45 |
| Teva Pharmaceuticals USA, Inc. | 2 | $39 |
| E.R. Squibb & Sons, L.L.C. | 2 | $39 |
| Vanda Pharmaceuticals Inc. | 1 | $23 |
Products named: ARISTADA, CAPLYTA, INVEGA SUSTENNA, COBENFY, ABILIFY ASIMTUFII, HETLIOZ, AUSTEDO XR, UZEDY.
Industry payments across NC — which companies pay providers there.
